Target Name: VWA1
NCBI ID: G64856
Other Name(s): Von Willebrand factor A domain-related protein | DKFZp761O051 | von Willebrand factor A domain containing 1 | WARP | VWA1_HUMAN | Von Willebrand factor A domain containing 1, transcript variant 1 | Von Willebrand factor A domain-containing protein 1 (isoform 1) | Von Willebrand Factor A Domain-Containing 1 | HMNMYO | OTTHUMP00000220538 | von Willebrand factor A domain-containing protein 1 | VWA1 variant 1 | von Willebrand factor A domain-related protein | FLJ22215 | OTTHUMP00000003018

Von Willebrand Factor A: A Promising Therapeutic Target for Autoimmune Diseases

Von Willebrand factor A (VWF-A) is a protein that is expressed in various tissues throughout the body, including the heart, kidneys, and liver. It is a member of the von Willebrand disease (VWD) gene family, which is associated with the development of various autoimmune diseases, including autoimmune hemolytic anemia, autoimmune myocarditis, and autoimmune haptenosis. VWF-A plays a crucial role in the regulation of blood clotting and has been implicated in the development and progression of these autoimmune diseases.

The VWF-A protein is known for its ability to interact with integrins, which are a type of protein that is found on the surface of immune cells and tissue cells. Integrins help to regulate the movement of immune cells and play a key role in the formation of immune responses. VWF-A has been shown to interact with integrins such as CD71, CD73, and CD75, which are all involved in the regulation of cell adhesion and migration.

One of the unique features of VWF-A is its ability to regulate the activity of integrins. This is accomplished through the presence of a portion of VWF-A that is known as the N-terminal domain. This domain is known to be involved in the regulation of integrin interactions and has been shown to play a role in the development of autoimmune diseases.

In addition to its role in integrin regulation, VWF-A has also been shown to play a role in the regulation of cell signaling pathways. This is accomplished through the presence of a portion of VWF-A that is known as the C-terminal domain. This domain is known to be involved in the regulation of several signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway.

The VWF-A protein is also known for its ability to interact with several protein kinases, including CSK (Src/FAK kinase) and TPF (Tyrosine phosphotransfer factor). These interactions are important for the regulation of cellular signaling pathways and have been implicated in the development and progression of autoimmune diseases.

Despite its many functions, the precise mechanism by which VWF-A promotes autoimmune diseases is not well understood. However, several studies have shown that VWF-A plays a role in the regulation of immune cell function and the development of autoimmune diseases.

One of the most promising avenues for research into the role of VWF-A in autoimmune diseases is the use of small molecules as therapeutic interventions. Many small molecules have been shown to interact with VWF-A and have the potential to be used as anti-inflammatory or immunosuppressive agents.

In addition to its potential as a drug or biomarker, VWF-A is also of interest as a potential therapeutic target for the treatment of autoimmune diseases. By targeting the regulation of VWF-A function, researchers may be able to develop new treatments for these diseases.

Conclusion

Von Willebrand factor A (VWF-A) is a protein that has been shown to play a critical role in the regulation of blood clotting and the development and progression of autoimmune diseases. Its unique ability to interact with integrins and regulate signaling pathways makes it an attractive candidate for therapeutic intervention. Further research is needed to fully understand the role of VWF-A in autoimmune diseases and its potential as a drug or biomarker.

Protein Name: Von Willebrand Factor A Domain Containing 1

Functions: Promotes matrix assembly (By similarity). Involved in the organization of skeletal muscles and in the formation of neuromuscular junctions (Probable)

More Common Targets

VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64